MCQ
Biopharma SHAKTI - Strategy for Healthcare Advancement through Knowledge, Technology & Innovation MCQ - Practice Questions with Answers
Solve 5 Biopharma SHAKTI - Strategy for Healthcare Advancement through Knowledge, Technology & Innovation questions for RAS/RPSC preparation.
Practice questions
Q1Match List I with List II and select the correct code. List I: 1. Biopharma Discovery Grant Fund; 2. Discovery and Development Equity Fund; 3. India Clinical Trial Sites Network; 4. Regulatory strengthening. List II: P. Non-repayable support for early, high-risk research; Q. Government stake for later, capital-heavy product development; R. Nationally accredited trial capacity; S. Dedicated Scientific Review Cadre in CDSCO.
The Discovery Grant Fund supplies non-repayable support for early, risky research, while the Equity Fund uses a government stake for later product development. The trial-site network expands accredited clinical capacity, and regulatory strengthening creates a dedicated Scientific Review Cadre in CDSCO.
Q2Which one of the following correctly states the announced outlay and duration of Biopharma SHAKTI?
The Union Budget 2026-27 announced Biopharma SHAKTI with an outlay of ₹10,000 crore over the next five years. The strategy is intended to build domestic capacity for biologics and biosimilars, so option B reproduces both the notified amount and duration correctly.
Q3Consider the following statements about the education and clinical-research components of Biopharma SHAKTI: 1. It provides for establishing 3 new NIPERs and upgrading 7 existing NIPERs. 2. It envisages a nationally accredited network of 1,000 clinical trial sites under ICMR. Which of the statements given above is/are correct?
Both statements are correct. The strategy expands the biopharma education network through 3 new NIPERs and upgrades 7 existing institutes. It also creates a nationally accredited network of 1,000 clinical trial sites under ICMR to strengthen India's capacity for advanced trials.
Q4Consider the following Assertion (A) and Reason (R) about Biopharma SHAKTI. Assertion (A): Its financing design supports the movement of promising biopharma candidates from early discovery towards later product-development milestones. Reason (R): It combines a non-repayable Biopharma Discovery Grant Fund for early research with a Discovery and Development Equity Fund in which the government takes a stake for later capital-heavy development. Select the correct answer.
Both the assertion and reason are true, and the reason explains the assertion. Non-repayable grants reduce the risk of early discovery, where private capital is scarce, while structured government equity supports costly later development. Together they connect discovery with product milestones rather than operating as a pure loan or subsidy.
Q5Which one of the following best describes the institutional location and nature of Biopharma SHAKTI?
Biopharma SHAKTI is anchored in the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers. It is a central-sector, supply-side strategy covering manufacturing, research, clinical trials and regulation, rather than a welfare, insurance or direct-benefit programme.
You've seen 5 of 5 sample questions
Unlimited practice on Biopharma SHAKTI - Strategy for Healthcare Advancement through Knowledge, Technology & Innovation comes with the RAS Test Series + Practice pack or Gate Pass.